Olasecuthones A-E: Undescribed xanthones from Securidaca Longipedunculata Fresen (Polygalaceae)

IF 1.4 4区生物学 Q4 CHEMISTRY, MEDICINAL

Phytochemistry Letters Pub Date : 2025-08-28 DOI:10.1016/j.phytol.2025.103040

Abdulkabir Oladele Oladimeji , K. Suresh Babu

引用次数: 0

Abstract

The phytochemical analysis of the root components of Securidaca longipedunculata resulted in the identification of four previously unreported xanthones, designated as olasecuthones A-D (1–4), alongside sixteen previously known compounds (5–20). The structural elucidation of these compounds was predominantly achieved through one-dimensional and two-dimensional nuclear magnetic resonance (NMR) spectroscopy, complemented by X-ray crystallographic analysis employing molybdenum Kα radiation, and with further validation through comparison with the existing literature. This research also marks the first report of the single crystal X-ray structure characterization of 2-hydroxy-1,7-dimethoxyxanthone (6).

查看原文本刊更多论文

Olasecuthones A-E：未描述的山仙子（蓼科）中的山酮类化合物

通过对长柄Securidaca longipedunculata根成分的植物化学分析，鉴定出4种以前未报道的山酮类化合物，命名为olasecuthones A-D(1-4)，以及16种以前已知的化合物（5-20）。这些化合物的结构解析主要是通过一维和二维核磁共振（NMR）光谱来实现的，辅以使用钼Kα辐射的x射线晶体学分析，并通过与现有文献的比较进一步验证。本研究也首次报道了2-羟基-1,7-二甲氧基山酮的单晶x射线结构表征(6)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Phytochemistry Letters 生物-生化与分子生物学

CiteScore

3.00

自引率

11.80%

发文量

190

审稿时长

34 days

期刊介绍： Phytochemistry Letters invites rapid communications on all aspects of natural product research including: • Structural elucidation of natural products • Analytical evaluation of herbal medicines • Clinical efficacy, safety and pharmacovigilance of herbal medicines • Natural product biosynthesis • Natural product synthesis and chemical modification • Natural product metabolism • Chemical ecology • Biotechnology • Bioassay-guided isolation • Pharmacognosy • Pharmacology of natural products • Metabolomics • Ethnobotany and traditional usage • Genetics of natural products Manuscripts that detail the isolation of just one new compound are not substantial enough to be sent out of review and are out of scope. Furthermore, where pharmacology has been performed on one new compound to increase the amount of novel data, the pharmacology must be substantial and/or related to the medicinal use of the producing organism.